Seegene unveils strategies for global expansion at 2022 AACC
Company has taken part in the Annual
Scientific Meeting & Clinical Lab Expo since 2007This year’s event showcased its In-life
PCR campaign and STARlet-AIOSSeegene also displayed Novaplex™ assays,
including a test for detecting the monkeypox virus Seoul (July 28, 2022) Seegene Inc.
(096530), South Korea’s leading molecular diagnostics company, took part in the
2022 American Association of Clinical Chemistry (AACC) Annual Scientific
Meeting & Clinical Lab Expo in Chicago between July 26-28. Seegene
showcased its ‘In-life PCR’ campaign and its automated PCR Solution ‘STARlet-AIOS,’
as well as a suite of Novaplex™ assays, including a test for detecting the
monkeypox virus.The AACC meeting, now in its 74th
year, is the world’s largest gathering for the clinical laboratory and
diagnostics industry. More than 200 global companies, participated in this
year’s event. Seegene has taken part since 2007. In-life PCR: Keeping
communities safe through regular testingSeegene’s In-life PCR
campaign is a global initiative that emphasizes regular testing of
COVID-19, influenza, and cold viruses to identify infected individuals with
mild or no symptoms. This, in turn, may help curb widespread transmissions
within communities. The campaign will target venues that require face-to-face
interactions, such as schools, workplaces, and nursing homes. Seegene will use the Allplex™
SARS-CoV-2/FluA/FluB/RSV Assay, which can simultaneously detect COVID-19, flu A
and B, and respiratory syncytial virus (RSV), and will provide the necessary
PCR instruments.At the AACC meeting,
Seegene shared the campaign’s mission with participants and potential partners.
The company recently partnered with a test center in Vietnam to launch the
campaign and is working to expand the initiative to other regions, including
Europe and the Middle East. Enabling PCR
testing at small clinics with fully automated STARlet-AIOSSeegene’s STARlet-AIOS
(All-in-One System) will provide “hands-free” PCR workflows, from nucleic acid
extraction to result analysis. It is a fully automated (sample in – result out)
system that can be operated by those with minimal PCR experience. STARlet-AIOS is compatible
with a wide range of Seegene’s syndromic assays that can simultaneously test
for multiple targets with just a single tube. The company has obtained
EU-approval for over 30 tests that can detect COVID-19 and other respiratory
illnesses, human papillomavirus (HPV), other sexually transmitted infections
(STIs), gastrointestinal infections (GIs), and drug resistance (DR).STARlet-AIOS, which has
a smaller footprint compared to other solutions in the market, is composed of
independent and detachable PCR component instruments. Test centers can purchase
the full set or modify their systems by adding detachable modules. The latter can
be an eco-friendly option as it doesn’t require additional resources or
manufacturing.The modular nature of the system also makes
maintenance convenient, while authorization procedures are easier as it
combines pre-approved instruments. It is the world’s first “assembled” solution
that enables automated syndromic testing.These features will allow small hospitals,
local clinics, and public health centers to integrate STARlet-AIOS into their
workflows. The STARlet-AIOS is expected to play a pivotal role in the
expansion of Seegene’s In-life PCR campaign. Also, at the 2022 AACC, Seegene displayed its
Research Use Only (RUO) product line, Novaplex™, for the U.S. market. This
portfolio includes a dedicated test for detecting the monkeypox virus.
Seegene recently strengthened its U.S.
leadership team as part of efforts to extend its global success to the U.S.
market.
Jul 29, 2022View Detail >
